Breast cancer bone metastases: pathogenesis and therapeutic targets
© 2018 Elsevier Ltd. Breast cancer is the most common cancer affecting women worldwide, with bone metastases presenting as the most common site of disease recurrence. Bone metastases secondary to breast cancer negatively impacts patient survival, mobility, and quality of life. Furthermore, the clini...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Pergamon
2018
|
| Online Access: | http://hdl.handle.net/20.500.11937/65663 |
| _version_ | 1848761177054642176 |
|---|---|
| author | Brook, Naomi Brook, Erin Dharmarajan, Arunasalam Dass, Crispin Chan, Arlene |
| author_facet | Brook, Naomi Brook, Erin Dharmarajan, Arunasalam Dass, Crispin Chan, Arlene |
| author_sort | Brook, Naomi |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | © 2018 Elsevier Ltd. Breast cancer is the most common cancer affecting women worldwide, with bone metastases presenting as the most common site of disease recurrence. Bone metastases secondary to breast cancer negatively impacts patient survival, mobility, and quality of life. Furthermore, the clinical complications of breast cancer bone metastases are associated with significant financial burden to the individual and society. The molecular mechanisms involved in the metastasis, colonisation, and proliferation of breast cancer cells in bone are complex and involve crosstalk between breast cancer cells and the bone microenvironment. The ability of metastatic breast cancer cells to hijack normal biological processes involved in bone remodelling is a key driver of osteolytic and osteoblastic bone lesions. As such, our understanding of how breast cancer cells manipulate normal bone remodelling pathways is essential for the development of new therapeutic agents to improve patient outcomes. In this review, we discuss bone remodelling under normal physiological conditions and explore key pathways dysregulated in breast cancer metastasis to bone. We provide an overview of systemic therapies currently recommended for the treatment of breast cancer bone metastases and highlight emerging therapeutic targets. |
| first_indexed | 2025-11-14T10:27:31Z |
| format | Journal Article |
| id | curtin-20.500.11937-65663 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T10:27:31Z |
| publishDate | 2018 |
| publisher | Pergamon |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-656632018-06-08T02:55:41Z Breast cancer bone metastases: pathogenesis and therapeutic targets Brook, Naomi Brook, Erin Dharmarajan, Arunasalam Dass, Crispin Chan, Arlene © 2018 Elsevier Ltd. Breast cancer is the most common cancer affecting women worldwide, with bone metastases presenting as the most common site of disease recurrence. Bone metastases secondary to breast cancer negatively impacts patient survival, mobility, and quality of life. Furthermore, the clinical complications of breast cancer bone metastases are associated with significant financial burden to the individual and society. The molecular mechanisms involved in the metastasis, colonisation, and proliferation of breast cancer cells in bone are complex and involve crosstalk between breast cancer cells and the bone microenvironment. The ability of metastatic breast cancer cells to hijack normal biological processes involved in bone remodelling is a key driver of osteolytic and osteoblastic bone lesions. As such, our understanding of how breast cancer cells manipulate normal bone remodelling pathways is essential for the development of new therapeutic agents to improve patient outcomes. In this review, we discuss bone remodelling under normal physiological conditions and explore key pathways dysregulated in breast cancer metastasis to bone. We provide an overview of systemic therapies currently recommended for the treatment of breast cancer bone metastases and highlight emerging therapeutic targets. 2018 Journal Article http://hdl.handle.net/20.500.11937/65663 10.1016/j.biocel.2018.01.003 Pergamon restricted |
| spellingShingle | Brook, Naomi Brook, Erin Dharmarajan, Arunasalam Dass, Crispin Chan, Arlene Breast cancer bone metastases: pathogenesis and therapeutic targets |
| title | Breast cancer bone metastases: pathogenesis and therapeutic targets |
| title_full | Breast cancer bone metastases: pathogenesis and therapeutic targets |
| title_fullStr | Breast cancer bone metastases: pathogenesis and therapeutic targets |
| title_full_unstemmed | Breast cancer bone metastases: pathogenesis and therapeutic targets |
| title_short | Breast cancer bone metastases: pathogenesis and therapeutic targets |
| title_sort | breast cancer bone metastases: pathogenesis and therapeutic targets |
| url | http://hdl.handle.net/20.500.11937/65663 |